Sanofi (SNY) announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, for treating adults with moderate-to-severe asthma. The company also provided updates on other pipeline candidates, which are in mid- to late-stage studies for treating various respiratory indications.Preliminary Data From SNY's Asthma Study on AmlitelimabPreliminary data from the TIDE-Asthma study showed that treatment with the highest dose level of amlitelimab failed to meet the pr ...